MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Lewy bodies"

  • 2025 International Congress

    Lewy Pathology in the Peripheral Nervous System of SNCA Duplication

    G. Beck, M. Yamadera, A. Tarutani, Y. Yonenobu, M. Hasegawa, S. Murayama, H. Mochizuki (Suita, Japan)

    Objective: This study aimed to investigate the degree, distribution, and biochemical profile of phosphorylated α-synuclein (p-α-syn) in the peripheral nervous system of patients with SNCA…
  • 2025 International Congress

    Patient-derived α-synuclein seed amplification as a tool for evaluating small molecule aggregation inhibitors for Parkinson’s disease and Lewy Body Dementia therapeutics

    K. Luk, B. Li, S. Song, N. Newman (Cambridge, USA)

    Objective: To validate on-target engagement of disease-relevant ⍺-synuclein (a-syn) aggregates by WTX-607, WaveBreak’s small-molecule clinical candidate for Parkinson’s disease (PD) and Lewy body dementia (LBD),…
  • 2025 International Congress

    Validation of CSF Alpha-synuclein SAA in an Autopsy Cohort with Systemic Assessment of Lewy Pathology Including the Body

    M. Kurihara, T. Matsubara, K. Satoh, A. Arakawa, M. Hara, K. Kanemaru, A. Iwata, S. Murayama, Y. Saito (Tokyo, Japan)

    Objective: Based on the recent recommendations by international neuropathologists [1], we attempted to evaluate the diagnostic accuracy of cerebrospinal fluid (CSF) alpha-synuclein (α-syn) seeding amplification…
  • 2025 International Congress

    Sex Differences for Autopsy-Confirmed Prodromal Lewy Body Dementia

    F. Dino, L. Gunn-Sandell, A. Tsai, D. Carter, Y. Wang, E. Bayram (Aurora, USA)

    Objective: To assess sex differences in prodromal Lewy body dementia (LBD) compared to Alzheimer’s disease (AD) Background: Identifying LBD at the prodromal stage can provide…
  • 2025 International Congress

    Design of the Phase 2, Double-Blind, Placebo-Controlled, Multicenter Study Investigating the Efficacy and Safety of ACP-204, a Novel 5-HT2A Inverse Agonist, in Adults With Lewy Body Dementia Psychosis

    R. Nunez, S. Friend, B. Howell, S. Pathak, B. Dirks, X. Feng, V. Abler (San Diego, USA)

    Objective: To present the design for a study of ACP-204 efficacy and safety in adults with Lewy body dementia psychosis (LBDP), including Parkinson’s disease dementia…
  • 2025 International Congress

    Visual processing impairments are predictive of dementia in Lewy Body disease

    E. Mccann, F. Coleman, A. Fazlollahi, S. Lee, J. O'Sullivan, P. Nestor (Herston, Australia)

    Objective: To characterise visual processing impairments as an early feature of dementia in Lewy Body disease (LBD). Background: Occipital and posterior parieto-temporal hypometabolism is a…
  • 2024 International Congress

    Accuracy of Clinical features for Substantia Nigra Hypopigmentation and Cortical Lewy Body Presence in the Oldest-Old: The 90+ Study

    R. Rajmohan, Z. Al-Darsani, N. Phielipp, T. Montine, M. Corrada, C. Kawas (Orange, USA)

    Objective: To improve clinical diagnostic accuracy of Lewy Body Dementia (LBD), we assessed if frontal release signs are a useful screening tool for cortical Lewy…
  • 2024 International Congress

    Concordance of Neuropathologic Diagnosis of Lewy Body Disease with Baseline Alpha-Synuclein Seed Amplification Assay in PPMI

    K. Poston, J. Ha, T. Montine, S. Bukhari, T. Foroud, L. Heathers, K. Nudelman, I. Aldecoa, A. Garrido, J. Franz, C. Stadelmann, J-P. Vonsattel, A. Siderowf, L. Chahine, T. Simuni, K. Marek (Stanford, USA)

    Objective: To determine whether the alpha-synuclein seed amplification assay (aSyn-SAA) performed on cerebral spinal fluid (CSF) collected at the baseline (BL) PPMI visit is concordant…
  • 2024 International Congress

    α-Synuclein Pathology Across Movement Disorders and Neurodegenerative Diseases by Seed Amplification Assay

    S. Weber, C. Farris, Y. Ma, M. Dakna, M. Starke, C. Trenkwalder, L. Concha-Marambio, B. Mollenhauer (Goettingen, Germany)

    Objective: To assess the frequency of pathological α-synuclein (αSyn) in various movement disorders and neurodegenerative diseases from a specialized movement disorder clinic by αSyn seed…
  • 2024 International Congress

    Case Report: An Unusual Case of Corticobasal Syndrome

    A. Ly, M. King, C. Sherer, J. Crook, A. Schindler, L. Danielian, K. Porter, A. Snyder, J. Kwan, S. Scholz (Bethesda, USA)

    Objective: To describe a patient with corticobasal syndrome (CBS) and biomarker evidence of multiple proteinopathies. Background: CBS is a clinically heterogeneous syndrome caused by several…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • …
  • 10
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Welcome to the MDS Abstracts Site
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • #24970 (not found)
  • Life expectancy with and without Parkinson’s disease in the general population
  • Advanced Search
  • Effect of marijuana on Essential Tremor: A case report
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley